Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 8/2016

04.05.2016 | Review

Ovarian stimulation in the luteal phase: systematic review and meta-analysis

verfasst von: C. E. Boots, M. Meister, A. R. Cooper, A. Hardi, E. S. Jungheim

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to evaluate whether outcomes are different if controlled ovarian stimulation (COS) is started in the luteal phase rather than the follicular phase.

Methods

A systematic review and meta-analysis was performed. Sixteen studies were included in the qualitative analysis, and eight studies with a total of 338 women were included in the quantitative analysis.

Results

Cycles initiated in the luteal phase were slightly longer (WMD 1.1 days, 95 % CI 0.39–1.9) and utilized more total gonadotropins (WMD 817 IU, 95 % CI 489–1144). However, no differences were noted in peak estradiol levels (WMD −411 pg/ml, 95 % CI −906–84.7) or in the total number of oocytes retrieved (WMD 0.52 oocytes, 95 % CI −0.74–1.7). There were slightly more mature oocytes retrieved in the luteal phase (WMD 0.77 oocytes, 95 % CI 0.21–1.3), and fertilization rates were significantly higher (WMD 10 %, 95 % CI 0.03–0.18). While only three studies reported pregnancy outcomes, no difference was noted in the FET pregnancy rates after COS in the luteal versus follicular phase (RR 0.95, 95 % CI 0.56–1.7).
A post hoc power analysis revealed that a sample of this size was sufficient to detect a clinically meaningful difference of 2 oocytes retrieved with 93 % power.

Conclusion

Although initiating COS in the luteal phase requires a longer stimulation and a higher dose of total gonadotropin, these differences are not clinically significant. Furthermore, COS initiated in the luteal phase does not compromise the quantity or quality of oocytes retrieved compared to outcomes of traditional stimulation in the follicular phase.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission posted to the SEER website. 2015. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2012/​, based on November 2014 SEER data submission posted to the SEER website. 2015.
2.
Zurück zum Zitat Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–31.CrossRefPubMed Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–31.CrossRefPubMed
3.
Zurück zum Zitat Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.CrossRefPubMed Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.CrossRefPubMed
4.
Zurück zum Zitat Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 2013;100(5):1214–23. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 2013;100(5):1214–23.
5.
Zurück zum Zitat Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril. 2013;99(6):1476–84.CrossRefPubMed Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril. 2013;99(6):1476–84.CrossRefPubMed
6.
Zurück zum Zitat Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003;80(1):116–22.CrossRefPubMed Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003;80(1):116–22.CrossRefPubMed
7.
Zurück zum Zitat von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009;92(4):1360–5.CrossRef von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009;92(4):1360–5.CrossRef
8.
Zurück zum Zitat Sonmezer M, Turkcuoglu I, Coskun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 2011;95(6). Sonmezer M, Turkcuoglu I, Coskun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 2011;95(6).
9.
Zurück zum Zitat Nayak SR, Wakim AN. Random-start gonadotropin-releasing hormone (GnRH) antagonist-treated cycles with GnRH agonist trigger for fertility preservation. Fertil Steril. 2011;96(1):e51–4.CrossRefPubMed Nayak SR, Wakim AN. Random-start gonadotropin-releasing hormone (GnRH) antagonist-treated cycles with GnRH agonist trigger for fertility preservation. Fertil Steril. 2011;96(1):e51–4.CrossRefPubMed
10.
Zurück zum Zitat Ozkaya E, San Roman G, Oktay K. Luteal phase GnRHa trigger in random start fertility preservation cycles. J Assist Reprod Genet. 2012;29(6):503–5.CrossRefPubMedPubMedCentral Ozkaya E, San Roman G, Oktay K. Luteal phase GnRHa trigger in random start fertility preservation cycles. J Assist Reprod Genet. 2012;29(6):503–5.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80.CrossRefPubMed Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80.CrossRefPubMed
12.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.CrossRefPubMed Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.CrossRefPubMed
13.
Zurück zum Zitat Higgins J, Green S (ed). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Higgins J, Green S (ed). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.​cochrane-handbook.​org.
14.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMed DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMed
15.
Zurück zum Zitat Higgins J, Thompson S. Quantifying heterogeneity in a meta‐analysis. Stat Med. 2002;21:1539–58.CrossRefPubMed Higgins J, Thompson S. Quantifying heterogeneity in a meta‐analysis. Stat Med. 2002;21:1539–58.CrossRefPubMed
16.
Zurück zum Zitat Hussein G, Lood M. Random-start IVF treatment: an emergent fertility preservation technique between cytotoxic treatment courses and stem-cell transplantation in acute myelocytic leukemia. Middle East Fertil Soc J 2015;20:297–300. Hussein G, Lood M. Random-start IVF treatment: an emergent fertility preservation technique between cytotoxic treatment courses and stem-cell transplantation in acute myelocytic leukemia. Middle East Fertil Soc J 2015;20:297–300.
17.
Zurück zum Zitat Friedman BE, Pao S, Westphal LM, Lathi RB. Oocyte retrieval following continued stimulation five days beyond ovulation yields live birth after frozen embryo transfer. J Assist Reprod Genet. 2012;29(5):433–5.CrossRefPubMedPubMedCentral Friedman BE, Pao S, Westphal LM, Lathi RB. Oocyte retrieval following continued stimulation five days beyond ovulation yields live birth after frozen embryo transfer. J Assist Reprod Genet. 2012;29(5):433–5.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Friedman BE, Pao S, Westphal LM, Lathi RB. Successful oocyte retrieval and fertilization following continued stimulation 5 days beyond ovulation. Fertil Steril. 2011;95(4):S13.CrossRef Friedman BE, Pao S, Westphal LM, Lathi RB. Successful oocyte retrieval and fertilization following continued stimulation 5 days beyond ovulation. Fertil Steril. 2011;95(4):S13.CrossRef
19.
Zurück zum Zitat Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012;97(1):125–33.CrossRefPubMed Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012;97(1):125–33.CrossRefPubMed
20.
Zurück zum Zitat Huober-Zeeb C, Lawrenz B, Popovici RM, Strowitzki T, Germeyer A, Stute P, et al. Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. Fertil Steril. 2011;95(1):342–4.CrossRefPubMed Huober-Zeeb C, Lawrenz B, Popovici RM, Strowitzki T, Germeyer A, Stute P, et al. Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. Fertil Steril. 2011;95(1):342–4.CrossRefPubMed
21.
Zurück zum Zitat Lawrenz B, Jauckus J, Kupka MS, Strowitzki T, von Wolff M. Fertility preservation in >1,000 patients: patient’s characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet. 2011;283(3):651–6.CrossRefPubMed Lawrenz B, Jauckus J, Kupka MS, Strowitzki T, von Wolff M. Fertility preservation in >1,000 patients: patient’s characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet. 2011;283(3):651–6.CrossRefPubMed
22.
Zurück zum Zitat Lawrenz B, Neunhoeffer E, Henes M, Lessmann-Bechle S, Kramer B, Fehm T. Management of fertility preservation in young breast cancer patients in a large breast cancer centre. Arch Gynecol Obstet. 2010;282(5):547–51.CrossRefPubMed Lawrenz B, Neunhoeffer E, Henes M, Lessmann-Bechle S, Kramer B, Fehm T. Management of fertility preservation in young breast cancer patients in a large breast cancer centre. Arch Gynecol Obstet. 2010;282(5):547–51.CrossRefPubMed
23.
Zurück zum Zitat El-Toukhy T, Taranissi M. Which is more counterproductive: a brief delay or “start anyway”? Hum Reprod Oxf Engl. 2006;21(9):2456–7. author reply 2457–8.CrossRef El-Toukhy T, Taranissi M. Which is more counterproductive: a brief delay or “start anyway”? Hum Reprod Oxf Engl. 2006;21(9):2456–7. author reply 2457–8.CrossRef
24.
Zurück zum Zitat von Wolff M, Donnez J, Hovatta O, Keros V, Maltaris T, Montag M, et al. Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy—a technique in its infancy but already successful in fertility preservation. Eur J Cancer Oxf Engl 1990. 2009;45(9):1547–53. von Wolff M, Donnez J, Hovatta O, Keros V, Maltaris T, Montag M, et al. Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy—a technique in its infancy but already successful in fertility preservation. Eur J Cancer Oxf Engl 1990. 2009;45(9):1547–53.
25.
Zurück zum Zitat Shalom-Paz E, Holzer HEG. Fertility preservation for cancer patients. Current Options Minerva Ginecol. 2011;63(6):517–30.PubMed Shalom-Paz E, Holzer HEG. Fertility preservation for cancer patients. Current Options Minerva Ginecol. 2011;63(6):517–30.PubMed
26.
Zurück zum Zitat von Wolff M, Zeeb C, Lawrenz B, Germeyer A, Neunhoeffer E, Strowitzki T. Cryopreservation of ovarian tissue and cryopreservation of oocytes can be efficiently combined and performed within 2 weeks before chemotherapy. Mol Hum Reprod. 2009;24:i157.CrossRef von Wolff M, Zeeb C, Lawrenz B, Germeyer A, Neunhoeffer E, Strowitzki T. Cryopreservation of ovarian tissue and cryopreservation of oocytes can be efficiently combined and performed within 2 weeks before chemotherapy. Mol Hum Reprod. 2009;24:i157.CrossRef
27.
Zurück zum Zitat Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online. 2014;29(6):684–91.CrossRefPubMed Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online. 2014;29(6):684–91.CrossRefPubMed
28.
Zurück zum Zitat Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014;101(1):105–11.CrossRefPubMed Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014;101(1):105–11.CrossRefPubMed
29.
Zurück zum Zitat Martinez F, Clua E, Devesa M, Rodriguez I, Arroyo G, Gonzalez C, et al. Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes. Fertil Steril. 2014;102(5):1307–11.CrossRefPubMed Martinez F, Clua E, Devesa M, Rodriguez I, Arroyo G, Gonzalez C, et al. Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes. Fertil Steril. 2014;102(5):1307–11.CrossRefPubMed
30.
Zurück zum Zitat Kim JH, Kim SK, Lee HJ, Lee JR, Jee BC, Suh CS, et al. Efficacy of random-start controlled ovarian stimulation in cancer patients. J Korean Med Sci. 2015;30(3):290.CrossRefPubMedPubMedCentral Kim JH, Kim SK, Lee HJ, Lee JR, Jee BC, Suh CS, et al. Efficacy of random-start controlled ovarian stimulation in cancer patients. J Korean Med Sci. 2015;30(3):290.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Rashidi BH, Tehrani ES, Ghaffari F. Ovarian stimulation for emergency fertility preservation in cancer patients: a case series study. Gynecol Oncol Rep. 2014;10:19–21.CrossRefPubMedPubMedCentral Rashidi BH, Tehrani ES, Ghaffari F. Ovarian stimulation for emergency fertility preservation in cancer patients: a case series study. Gynecol Oncol Rep. 2014;10:19–21.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Suikkari AM, Tulppala M, Tuuri T, Hovatta O, Barnes F. Luteal phase start of low-dose FSH priming of follicles results in an efficient recovery, maturation and fertilization of immature human oocytes. Hum Reprod Oxf Engl. 2000;15(4):747–51.CrossRef Suikkari AM, Tulppala M, Tuuri T, Hovatta O, Barnes F. Luteal phase start of low-dose FSH priming of follicles results in an efficient recovery, maturation and fertilization of immature human oocytes. Hum Reprod Oxf Engl. 2000;15(4):747–51.CrossRef
33.
Zurück zum Zitat Buendgen NK, Schultze-Mosgau A, Cordes T, Diedrich K, Griesinger G. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study. Arch Gynecol Obstet. 2013;288(4):901–4.CrossRefPubMed Buendgen NK, Schultze-Mosgau A, Cordes T, Diedrich K, Griesinger G. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study. Arch Gynecol Obstet. 2013;288(4):901–4.CrossRefPubMed
34.
Zurück zum Zitat Maman E, Meirow D, Brengauz M, Raanani H, Dor J, Hourvitz A. Luteal phase oocyte retrieval and in vitro maturation is an optional procedure for urgent fertility preservation. Fertil Steril. 2011;95(1):64–7.CrossRefPubMed Maman E, Meirow D, Brengauz M, Raanani H, Dor J, Hourvitz A. Luteal phase oocyte retrieval and in vitro maturation is an optional procedure for urgent fertility preservation. Fertil Steril. 2011;95(1):64–7.CrossRefPubMed
35.
Zurück zum Zitat Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet. 2010;27(8):491–4.CrossRefPubMedPubMedCentral Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet. 2010;27(8):491–4.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Dittrich R, Lotz L, Mueller A, Hoffmann I, Wachter DL, Amann KU, et al. Oncofertility: combination of ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval. Reprod Biol Endocrinol. 2013;11:19.CrossRefPubMedPubMedCentral Dittrich R, Lotz L, Mueller A, Hoffmann I, Wachter DL, Amann KU, et al. Oncofertility: combination of ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval. Reprod Biol Endocrinol. 2013;11:19.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Keskin U, Ercan CM, Yilmaz A, Babacan A, Korkmaz C, Duru NK, et al. Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature. J Pak Med Assoc. 2014;64(7):830–2.PubMed Keskin U, Ercan CM, Yilmaz A, Babacan A, Korkmaz C, Duru NK, et al. Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature. J Pak Med Assoc. 2014;64(7):830–2.PubMed
38.
Zurück zum Zitat Schuffner A, Skroch R, Garbelini M, Neto J, Peixoto A, da Rosa V. Ovarian stimulation in the follicular, late follicular and luteal phases: an ideal protocol for the preservation of fertility? J Bras Reprod Assist. 2012;16:91–3. Schuffner A, Skroch R, Garbelini M, Neto J, Peixoto A, da Rosa V. Ovarian stimulation in the follicular, late follicular and luteal phases: an ideal protocol for the preservation of fertility? J Bras Reprod Assist. 2012;16:91–3.
39.
Zurück zum Zitat Reynolds KA, Grindler NM, Rhee JS, Cooper AR, Ratts VS, Carson KR, et al. Variability in the practice of fertility preservation for patients with cancer. PLoS One. 2015;10(5):e0127335.CrossRefPubMedPubMedCentral Reynolds KA, Grindler NM, Rhee JS, Cooper AR, Ratts VS, Carson KR, et al. Variability in the practice of fertility preservation for patients with cancer. PLoS One. 2015;10(5):e0127335.CrossRefPubMedPubMedCentral
Metadaten
Titel
Ovarian stimulation in the luteal phase: systematic review and meta-analysis
verfasst von
C. E. Boots
M. Meister
A. R. Cooper
A. Hardi
E. S. Jungheim
Publikationsdatum
04.05.2016
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 8/2016
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-016-0721-5

Weitere Artikel der Ausgabe 8/2016

Journal of Assisted Reproduction and Genetics 8/2016 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.